High-dose biotin therapy is beneficial in progressive multiple sclerosis (MS) and is expected to be adopted by a large number of patients. Biotin therapy leads to analytical interference in many immunoassays that utilize streptavidin-biotin capture techniques, yielding skewed results that can mimic various endocrine disorders. We aimed at exploring this interference, to be able to remove biotin and avoid misleading results.
We measured free triiodothyronine (fT3), free thyroxine (fT4), thyroid-stimulating hormone (TSH), parathyroid homrone (PTH), 25-hydroxyvitamin D (25OHD), follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, C-peptide, cortisol (Roche Diagnostics assays), biotin and its main metabolites (liquid chromatography tandem mass spectrometry) in 23 plasmas from MS patients and healthy volunteers receiving high-dose biotin, and in 39 biotin-unsupplemented patients, before and after a simple procedure (designated N5) designed to remove biotin by means of streptavidin-coated microparticles. We also assayed fT4, TSH and PTH in the 23 high-biotin plasmas using assays not employing streptavidin-biotin binding.
The biotin concentration ranged from 31.7 to 1160 µg/L in the 23 high-biotin plasmas samples. After the N5 protocol, the biotin concentration was below the detection limit in all but two samples (8.3 and 27.6 μg/L). Most hormones results were abnormal, but normalized after N5. All results with the alternative methods were normal except two slight PTH elevations. In the 39 biotin-unsupplemented patients, the N5 protocol did not affect the results for any of the hormones, apart from an 8.4% decrease in PTH.
We confirm that most streptavidin-biotin hormone immunoassays are affected by high biotin concentrations, leading to a risk of misdiagnosis. Our simple neutralization method efficiently suppresses biotin interference.
We are grateful to Marie-Helene Novotny for excellent technical assistance, and to Yohann Hervy (Laboratoire Atlanbio) for measurements of biotin and biotin metabolites concentrations.
Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.
Research funding: None declared.
Employment or leadership: FS and DB are employed by MedDAY Pharmaceuticals.
Honorarium: JCS reports lecture fees and/or travel/hotel expenses from DiaSorin, Roche Diagnostics, Abbott, Amgen, Shire, MSD, Lilly, Rottapharm, Meda.
Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.
2. Sedel F, Papeix C, Bellanger A, Touitou V, Lebrun-Frenay C, Galanaud D, et al. High doses of biotin in chronic progressive multiple sclerosis: a pilot study. Mult Scler Relat Disord 2015;4:159–69.10.1016/j.msard.2015.01.005Search in Google Scholar PubMed
3. Tourbah A, Lebrun-Frenay C, Edan G, Clanet M, Papeix C, Vukusic S, et al. MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: a randomised, double-blind, placebo-controlled study. Mult Scler 2016;22:1719–31.10.1177/1352458516667568Search in Google Scholar PubMed PubMed Central
4. Minkowsky A, Lee MN, Dowlatshahi M, Angell T, Mahrokhian L, Petrides AK, et al. High-dose biotin treatment for secondary progressive multiple sclerosis may interfere with thyroid assays. AACE Clin Case Rep 2016;2:e370–3.10.4158/EP161261.CRSearch in Google Scholar PubMed PubMed Central
5. Piketty M-L, Polak M, Flechtner I, Gonzales-Briceño L, Souberbielle J-C. False biochemical diagnosis of hyperthyroidism in streptavidin-biotin-based immunoassays: the problem of biotin intake and related interferences. Clin Chem Lab Med 2017;55:780–8.10.1515/cclm-2016-0606Search in Google Scholar PubMed
7. Elston MS, Sehgal S, Du Toit S, Yarndley T, Conaglen JV. Facticious Graves’ disease due to biotin immunoassay interference – A case and review of the literature. J Clin Endocrinol Metab 2016;101:3251–5.10.1210/jc.2016-1971Search in Google Scholar PubMed
8. Simó-Guerrero O, Giménez-Pérez G, Recsens-Garci A, Villà-Blasco C, Castells-Fusté I. False overt hyperthyroidism by interference in immunoassays. Endocrinol Nutr 2016;63:431–2.10.1016/j.endoen.2016.09.010Search in Google Scholar
9. Batista MC, Ferreira CE, Fauhaber AC, Hidal JT, Lottenberg SA, Mangueira CL. Biotin interference in immunoassays mimicking subclinical Graves’disease and hyperestrogenism: a case series. Clin Chem Lab Med 2017;55:e99–103.10.1515/cclm-2016-0628Search in Google Scholar PubMed
12. Peyro Saint Paul L, Debruyne D, Bernard D, Mock DM, Defer GL. Pharmacokinetics and pharmacodynamics of MD1003 (high dose biotin) in the treatment of progressive multiple sclerosis. Expert Opin Drug Metab Toxicol 2016;12:327–44.10.1517/17425255.2016.1136288Search in Google Scholar
13. Meany DL, Jan De Beur SM, Bill MJ, Sokoll LJ. A case of renal osteodystrophy with unexpected serum intact parathyroid hormone concentrations. Clin Chem 2009;55: 1737–41.10.1373/clinchem.2008.121921Search in Google Scholar
16. Burfeind K, Yadav V, Marks D. Hypothalamic dysfunction and multiple sclerosis: implication for fatigue and weight dysregulation. Curr Neurol Neurosci Rep 2016;16:98.10.1007/s11910-016-0700-3Search in Google Scholar
17. Powell D, Moss-Morris R, Liossi C, Schlotz W. Circadian cortisol and fatigue severity in relapsing-remitting multiple sclerosis. Psychoneuroendocrinology 2015;56:120–31.10.1016/j.psyneuen.2015.03.010Search in Google Scholar
18. Bove R, Musallam A, Healy BC, Raghavan K, Glantz BI, Bakshi R, et al. Low testosterone is associated with disability in men with multiple sclerosis. Mult Scler 2014;20:1584–92.10.1177/1352458514527864Search in Google Scholar
19. Foroughipour A, Norbakhsh V, Najafabadi SH, Meamar R. Evaluating sex hormone levels in reproductive age women with multiple sclerosis and their relationship with disease severity. J Res Med Sci 2012;17:882–5.Search in Google Scholar
21. Wijeratne NG, Doery JC, Lu ZX. Positive and negative interference in immunoassays following biotin ingestion: a pharmacokinetic study. Pathology 2012;44:674–5.10.1097/PAT.0b013e32835a3c17Search in Google Scholar PubMed
22. Joly D, Drueke TB, Alberti C, Houillier P, Lawson-Body E, Martin KJ, et al. Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional study. Am J Kidney Dis 2008;51:987–95.10.1053/j.ajkd.2008.01.017Search in Google Scholar PubMed
23. Henry JG, Sobki S, Arafat N. Interference by biotin therapy on measurement of TSH and FT4 by enzymeimmunoassay on Boehringer Mannheim ES700 analyser. Ann Clin Biochem 1996;33:162–3.10.1177/000456329603300214Search in Google Scholar PubMed
25. Mock DM, Nyalala JO, Raguseo RM. A direct streptavidin-binding assay does not accurately quantitate biotin in human urine. J Nutr 2001;131:2208–14.10.1093/jn/131.8.2208Search in Google Scholar PubMed
26. Seaborg E. Thyroid month January 2016: beware of biotin. In endocrine news. Washington, USA: Endocrine society, 2016:42. Available at: http://endocrinenews.endocrine.org/January-2016-thyroid-month-beware-of-biotin. Accessed: January 2016.Search in Google Scholar
The online version of this article (DOI: 10.1515/cclm-2016-1183) offers supplementary material, available to authorized users.
©2017 Walter de Gruyter GmbH, Berlin/Boston